Table 1.
Patient | Sex | Age | Diagnosis at Draw |
Current Diagnosis |
Relapses | MRI Changes |
Treatment at Draw |
Current Treatment |
Percent of PBs in Blood |
Percent of PBs in CSF |
PBs Sorted from Blood |
Number of Productive PB Sequences |
Plasma Brain ELISA |
Plasma Sy5y ELISA |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CIS Patients Included inGenetic Analysis | CIS924a | M | 69 | TM | TM | 0 | 0 | None | None | 7.1 | 33.3 | 144 | 47 | + | + |
CIS799a | F | 28 | CIS | RRMS | 0 | 0 | None | Avonex | 5.74 | 13.3 | 190 | 68 | + | + | |
CIS991a | F | 34 | CIS | TM | 0 | 0 | None | steroids | 3.3 | 15.4 | 73d | 25 | + | + | |
CIS111abc | F | 62 | CIS | PPMS | 0 | 0 | None | Avonex | 3.04 | 5.77 | 190d | 58 | - | + | |
CIS663a | F | 32 | TM | TM | 0 | 0 | None | None | 2.85 | 10.8 | 192 | 121 | - | + | |
CIS431abc | F | 27 | CIS | RRMS | 1 | 1 | None | Gilenya | 2.07 | 35.9 | 190d | 81 | + | + | |
ATM4 | M | 24 | CIS | RRMS | 0 | 0 | Prednisone | None | 1.54 | 16.1 | 176 | 28 | + | - | |
CIS353abc | F | 58 | CIS | RRMS | 1 | 1 | None | Copaxone | 1.46 | 11.4 | 190d | 51 | + | + | |
CIS683abc | F | 39 | CIS | RRMS | 0 | 0 | None | Tecfidera | 0.82 | 26.6 | 190d | 63 | - | - | |
| |||||||||||||||
CIS Patients Not Included inGenetic Analysis | CIS287ac | F | 45 | TM | TM | 0 | 0 | None | Betaseron | 6.58 | 37.9 | - | - | ||
CIS873ac | F | 19 | RRMS | RRMS | 0 | 0 | None | Avonex | 2.98 | 26 | + | + | |||
CIS527ac | F | 43 | CIS | RRMS | 0 | 0 | None | Copaxone | 1.81 | 14.1 | - | - | |||
CIS699a | F | 37 | CIS | RRMS | 0 | 0 | None | Avonex | 1.61 | 7.87 | - | + | |||
CIS787ac | M | 33 | CIS | RRMS | 0 | 0 | None | Copaxone | 1.45 | 36.9 | - | + | |||
CIS251ac | F | 53 | TM | Sarcoidosis | 0 | 0 | None | None | 1.43 | 2.57 | |||||
CIS942a | F | 52 | CIS | CIS | 0 | 0 | None | Copaxone | 1.19 | 12.2 | - | - | |||
CIS328ac | M | 32 | CIS | RRMS | 0 | 0 | None | Avonex | 0.64 | 2.41 | - | - | |||
CIS371ac | F | 56 | CIS | CIS | 0 | 0 | None | Copaxone | 0.51 | 13.9 | |||||
| |||||||||||||||
Patient | Sex | Age | Diagnosis at Draw | Current Diagnosis | AQP-4 Status | AQP-4 Test | Treatment at Draw | Current Treatment | Percent of PBs in Blood | Percent of PBs inCSF | PBs SortedFrom Blood | Number of Productive Sequences | Plasma Brain ELISA | Plasma Sy5y ELISA | |
| |||||||||||||||
NMO Patientsin GeneticAnalysis | NM0.1 | F | 55 | NMO | NMO | + | ELISA | None | Cellcept | 3.47 | n/a | 95 | 31 | + | + |
NM0.2 | F | 36 | NMO | NMO | + | ELISA | None | None | 0.22 | n/a | 83 | 15 | |||
NM0.7 | F | 54 | NMO | NMO | + | CBA | None | Cellcept | 4.09 | n/a | 94 | 32 | |||
NM0.8 | F | 64 | NMO | NMO | + | CBA | None | Rituxan | 2.43 | n/a | 94 | 25 | |||
| |||||||||||||||
NMO Patients Not Included inGenetic Analysis | NM0.3 | F | 39 | NMO | NMO | - | CBA | Cellcept | Cellcept | 1.05 | n/a | - | - | ||
NM0.4 | F | 61 | NMO | NMO | + | ELISA | Cellcept | Cellcept | 0.09 | n/a | - | - | |||
NM0.5 | F | 41 | NMO | NMO | + | ELISA | Cellcept | Rituxan | 1.08 | n/a | - | - | |||
NM0.6 | M | 47 | NMO | NMO | - | CBA | Cellcept | Rituxan | 1.01 | n/a | - | - | |||
NM0.9 | F | 53 | NMO | NMO | - | CBA | Cellcept | Cellcept | 1.34 | n/a | - | - | |||
NMO.10 | F | 61 | NMO | NMO | + | ELISA | Cellcept | Cellcept | 0.17 | n/a | - | - | |||
NM0.31 | F | 46 | NMO | NMO | + | Unknown | AZT | Unknown | 0 | n/a | |||||
NM0.33 | M | 38 | NMO | NMO | + | Unknown | Cellcept | Unknown | 5.97 | n/a | |||||
NMO.70 | F | 45 | NMO | NMO | + | Unknown | AZT | Unknown | 4.52 | n/a | |||||
NMO.260 | F | 47 | NMO | NMO | - | Unknown | Cellcept | Unknown | 3.02 | n/a | |||||
NM0.626 | M | 36 | NMO | NMO | - | Unknown | AZT | Unknown | 2.15 | n/a | |||||
NMO.740 | F | 29 | NMO | NMO | _ | Unknown | AZT | Unknown | 3.13 | n/a | |||||
NM0.745 | F | 50 | NMO | NMO | Unknown | Unknown | Cellcept | Unknown | 1.66 | n/a |
CSF and peripheral B cells previously studied by flow cytometry.
Peripheral B cells previously studied by genetic analysis.
CSF B cell previously studied by genetic analysis.
Memory B cells also sorted (productive/total sorted): CIS991: (49/95) CIS111: (14/94) CIS431: (71/188) CIS353: (54/190) CIS683: (61/188)